The promise of AI in healthcare often hinges on squeezing more value out of tests patients already undergo. That principle just earned San Diego-based CureMetrix a major industry nod: the company was named a 2026 Rising Star Winner in the Cancer, Screening & Early Detection category at the 8th Annual Digital Health Hub Foundation Digital Health & AI Awards, held during HLTH USA in Las Vegas.
The annual competition, which drew more than 1,300 participating companies from around the globe, uses a rigorous multi-stage evaluation process. Hundreds of experts spanning healthcare, technology, and investment vet the finalists, making the recognition a significant signal of clinical and commercial promise.
What sets CureMetrix apart is its FDA-cleared solution, cmAngio®, which detects, quantifies, and contextualizes breast arterial calcifications (BAC) from routine mammography images. Rather than requiring new scans or additional radiation exposure, the software gives radiologists objective, age-based BAC insights pulled directly from existing mammograms. This approach expands the pool of actionable information available to physicians without burdening patients with extra appointments or procedures.
Also worth a look: Hatfield.ai unveils HatfieldIQ, an AI platform that connects the dots across global risks and CVBBA names top dealmakers at 2026 conference, honoring brokers who closed millions in sales.
“This recognition is an exciting milestone for CureMetrix and a testament to the dedication of our entire team,” said Navid Alipour, CEO of CureMetrix. “We believe the future of healthcare is about making more meaningful information available from the imaging patients already receive. With cmAngio, we’re demonstrating how innovation can expand the value of routine mammography and provide physicians with additional insights to support more informed conversations about women’s health. We’re honored to receive this award and excited about the impact we can continue to make.”
CureMetrix hasn’t stopped iterating. The company has introduced age-based percentile and prevalence insights that give clinicians additional context for BAC findings relative to women of similar ages. These enhancements align with the company’s broader mission: making medical imaging more informative, accessible, and clinically valuable.
The Rising Star award underscores a growing appetite for technologies that wring more clinically relevant intelligence out of imaging studies already in the workflow, helping providers make sharper, more informed decisions.
CureMetrix extended its gratitude to the Digital Health Hub Foundation, HLTH USA, and the judging panel for recognizing innovation across the healthcare landscape.
Shannon Reimer
CureMetrix
Visit us on social media:
LinkedIn
Instagram
Facebook
X
Why it matters: As healthcare systems struggle with rising costs and limited specialist time, tools like cmAngio that extract cardiovascular risk signals from routine breast cancer screening could transform preventive care without adding system burden. This award signals that investors and clinicians alike see real potential in making every mammogram do double duty.